Erik Nordkamp, managing director of Pfizer UK, has been named as the new president of the Association of the British Pharmaceutical Industry (ABPI).
News
Data show Imnovid-based triple therapy PFS benefit in blood cancer
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Survey shows public support for NHS tax rise
The vast majority of the public would be willing to accept tax increases to secure significant improvements in the NHS, finds a new poll by Ipos Mori commissioned by the NHS Confederation.
Final NICE no for BMS’ Opdivo in urothelial carcinoma
The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
UK’s genome sequencing project will hit 100,000 by year-end
Genomics England says the 100,000 Genomes Project is “well on track” to reach its target of sequencing 100,000 genomes by the end of this year.
MSD’s antiviral Prevymis fails to win NICE backing
MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
FDA approves drug for excessive drooling
Merz Neuroscience’s Xeomin has become the first agent to be approved by the US Food and Drug Administration to treat excessive drooling.
RCGP urges parents to vaccinate children against measles
The Royal College of GPs is urging parents to get their children vaccinated in response to data highlighting a significant rise in cases in England.
Novartis to hand back rights to Aveo’s AV-380
Novartis is intending to hand back rights to Aveo Oncology’s experimental antibody AV-380, which it acquired in August 2015 in a deal valued at at least $326 million.
Cannabis-based meds beneficial for some conditions, finds UK review
The UK’s chief medical officer and advisor Professor Dame Sally Davies has concluded that there is evidence to show the therapeutic benefit of cannabis-based medicines for some conditions.
GDPR behind drop in pharma payment disclosure, says ABPI
GDPR has contributed to a decline in the number of healthcare professionals disclosing payments or benefits from the pharma industry, says the Association of the British Pharmaceutical Industry.
US priority review for Keytruda/chemo combo in first-line squamous NSCLC
US regulators have assigned a priority review to MSD’s application to market the immunotherapy Keytruda in combination with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC).
EU green light for Cimzia to treat psoriasis
The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
NICE says Tookad too expensive for prostate cancer
The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
Gov’t announces £215m investment in NHS health research
The government has announced an investment of £215 million to fund NHS health research aiming to “transform the lives” of millions of people living with a range of conditions.
